

January 20, 2013

# **Curriculum Vitae**

## **Amit Segev, MD, FESC**

---

**I.D. Number:** 2264753-1

**Israeli Medical License Number:** 26326

**Date and place of birth:** August 6, 1966, Tel-Aviv, Tel Aviv, Israel

**Marital status:** Married to Fani + 4 daughters (Lior, Mai, Aviv, Tal)

### **A. EDUCATION**

#### **Medical School:**

1984-1991: Faculty of Medicine – Technion, Israel Institute of Technology,  
Haifa, Israel – Academic Reserve Program

#### **Degrees & Licenses:**

- B.Sc. in Medical Sciences (with honor) - 1988
- Medical Doctor (M.D.) – 1992
- ECFMG (USMLE) Certificate: Number 0-458-861-2 (September, 1998)
- Specialist in Internal Medicine – 2000 (license number: 17926)
- Specialist in Cardiology – 2003 (license number: 20659)
- 4 semesters in Continuing Medical Education (CME) in cardiology, Tel Aviv University – 2000/1
- Clinical Interventional Cardiology Fellowship, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada – 2002 – 2004
- FESC – Fellow of the European Society of Cardiology – June 2008

### **C. ACADEMIC AND PROFESSIONAL EXPERIENCE**

- ***Rotating Internship*** (1991-1992): Rambam Medical Center, Haifa, Israel
- ***Army Service*** ○ Israeli Defense Forces (IDF) battalion and brigade medical officer  
(1992-1994) ○ Head of IDF Golan Heights Medical Center (1994-1996) ○ Highest rank - **Major**
- ***Residency in Internal Medicine*** (1996-1999): Department of Internal Medicine B, Meir General Hospital, Kfar-Saba, Sackler School of Medicine, Tel Aviv University, Israel
- ***Basic Sciences Research period*** (1998): Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
- ***Passed the 1<sup>st</sup> stage examination of the Israel Scientific Council in Internal Medicine – 1999***
- ***Passed the 2<sup>nd</sup> stage examination of the Israel Scientific Council in Internal Medicine – 1999***
- ***Residency in Cardiology*** (1999–2002): Department of Cardiology, Meir General Hospital, Kfar-Saba, Sackler School of Medicine, Tel Aviv University, Israel
- ***Passed the 1<sup>st</sup> stage examination of the Israel Scientific Council in Cardiology – 2001***
- ***Passed the 2<sup>nd</sup> stage examination of the Israel Scientific Council in Cardiology – 2001***
- ***Fellowship in Interventional Cardiology & Basic Cardiovascular Research*** (2002–2004): Terrence Donnelly Heart Center, The Roy and Ann Foss Cardiovascular Research Program and Interventional Cardiology Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
- ***Staff (Senior) Cardiologist*** (from 2004): Interventional Cardiology Unit, The Heart Institute, Chaim Sheba Medical Centre, Tel-Hashomer, Affiliated to Tel-Aviv University, Israel

- In charge of CME Cardiology Course – Sackler School of Medicine, Tel Aviv University. 2006-2009.
- ***Fellow of the European Society of cardiology – FESC*** – from 2008
- ***Treasurer, Israeli Working Group in Interventional Cardiology***, Israel Heart Society. 2009-2011
- ***Senior Lecturer (Assistant Professor) in Cardiology*** – Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel - from 2009
- In charge of Cardio-Vascular System Education and Course for 2<sup>nd</sup> year medical students – 4-year Program, Sackler School of Medicine, Tel-Aviv University – 2008-present
- ***Secretary General, The Israel Heart Society*** – 2011-present

**D. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS**

- 1) American Heart Association (AHA), 71<sup>st</sup> Scientific Sessions, 1998, Dallas, TX, USA (Abstract presenter)
- 2) American College of Cardiology (ACC), 51<sup>st</sup> Annual Scientific Sessions, 2002, Atlanta, GA, USA (Abstract presenter)
- 3) American Heart Association (AHA), 75<sup>th</sup> Scientific Sessions, 2002, Chicago, IL, USA (Abstract presenter)
- 4) Interventional Cardiology Fellows Course (Cardiovascular Research Foundation), 2003, San Jose, CA, USA
- 5) American Heart Association (AHA), 76<sup>th</sup> Scientific Sessions, 2003, Orlando, FL, USA (Abstract presenter)
- 6) Transcatheter Cardiovascular Therapeutics (TCT), 2003, Washington, DC, USA (Faculty member)
- 7) Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada (Abstract presenter)
- 8) 5<sup>th</sup> International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, 2003, Tel-Aviv, Israel (Abstract presenter)
- 9) American College of Cardiology (ACC), 53<sup>rd</sup> Annual Scientific Sessions, 2004, New Orleans, LA, USA (Abstract presenter)
- 10) Interventional Cardiology Fellows Course (Cardiovascular Research Foundation), 2004, San Jose, CA, USA
- 11) Transcatheter Cardiovascular Therapeutics (TCT), 2004, Washington, DC, USA (Faculty member, case presenter)
- 12) American Heart Association (AHA), 77<sup>th</sup> Scientific Sessions, 2004, New Orleans, LA, USA (Abstract presenter)
- 13) Global Cardiovascular Interventions (GCI), 2004, Frankfurt, Germany (Faculty member, Presenter)

- 14) 6<sup>th</sup> International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, 2004, Tel-Aviv, Israel (Presenter)
- 15) Transcatheter Cardiovascular Therapeutics (TCT), 2005, Washington, DC, USA (Faculty Member, Presenter)
- 16) EUROPCR, 2006, Paris, France (Faculty member, Presenter)
- 17) Transcatheter Cardiovascular Therapeutics (TCT), 2006, Washington, DC, USA (faculty member, Presenter)
- 18) EUROPCR, 2007, Barcelona, Spain (Faculty Member, Presenter)
- 19) EUROPCR, 2008, Barcelona, Spain (Faculty Member, Presenter)
- 20) Transcatheter Cardiovascular Therapeutics (TCT), 2008, Washington, DC, USA (Faculty member, Presenter)
- 21) Innovations in Cardiovascular Interventions (ICI), 2008, Tel-Aviv, Israel (Chair of session)
- 22) EUROPCR, 2009, Barcelona, Spain (Faculty Member, Presenter)
- 23) Montreal Interventional Cardiology Meeting, 2009, Montreal, Canada (Presenter, Panelist)
- 24) Horizons in Invasive Cardiology, 2009, Rambam Medical Center, Haifa, Israel (Panelist)
- 25) Transcatheter Cardiovascular Therapeutics (TCT), 2009, San Francisco, CA, USA (Faculty Member, Presenter)
- 26) Innovations in Cardiovascular Interventions (ICI), 2009, Tel-Aviv, Israel (Chairmen of session)
- 27) 7<sup>th</sup> International Chronic Total Occlusion Summit, February 2010, New York, NY, USA (Faculty Member, Presenter)
- 28) 57<sup>th</sup> Annual Conference of the Israel Heart Society, April 2010, Tel Aviv, Israel (Chairman of session, Reviewer of abstracts)
- 29) EUROPCR, June 2010, Paris, France (Faculty Member, Presenter)
- 30) Montreal Interventional Cardiology Meeting, June 2010, Montreal, Canada (Presenter, Panelist)
- 31) Horizons in Invasive Cardiology, 2010, Rambam Medical Center, Haifa,

Israel (Panelist)

- 32) Transcatheter Cardiovascular Therapeutics (TCT), September 2010, Washington, DC, USA (Faculty Member, Presenter, Panelist)
- 33) Biotronik Focus Group, 2010, Zurich, Switzerland (Presenter, Discussant)
- 34) Innovations in Cardiovascular Interventions (ICI), December 2010, Tel-Aviv, Israel (Chairmen of session, Operator – live cases)
- 35) Cardiovascular Research Technologies Meeting (CRT), February 2011, Washington, DC, USA (Faculty member, Chairman of session, Presenter)
- 36) 58<sup>th</sup> Annual Conference of the Israel Heart Society, April 2011, Tel Aviv, Israel (Reviewer of abstracts, Presenter)
- 37) India Live 2011 (interventional cardiology meeting), February 2011, Mumbai, India (Faculty member, Chairman of session)
- 38) TCT Mediterranean, March 2011, Antalya, Turkey (Live case operator)
- 39) Horizons in Invasive Cardiology, 2011, Rambam Medical Center, Haifa, Israel (Panelist)
- 40) ESC Congress, August 2011, Paris, France (Secretary General of IHS)
- 41) 2<sup>nd</sup> Transradial Workshop in Transradial Intervention, September 2011, Jerusalem, Israel (Faculty member, Presenter)
- 42) International Summit on Imaging and Intervention in Cardiology (ISIIC), September 2011, Katowice, Poland (Presenter, Faculty member, Panelist)
- 43) Transcatheter Cardiovascular Therapeutics (TCT), November 2011, San Francisco, CA, USA (Faculty Member, Panelist, Reviewer of abstracts)
- 44) 9<sup>th</sup> International Congress on Coronary Artery Disease (ICCAD), October 2011, Venice, Italy (Reviewer of abstracts)
- 45) Innovations in Cardiovascular Interventions (ICI), December 2011, Tel-Aviv, Israel (Faculty member, Presenter)
- 46) American College of Cardiology (ACC.12), Annual Scientific Sessions, March 2012, Chicago, IL, USA (Faculty member, presenter, Panelist)
- 47) **59<sup>th</sup> Annual Conference of the Israel Heart Society, April 2012, Tel Aviv, Israel (Main Organizer, Chair, Reviewer of abstracts)**

- 48) The 61<sup>st</sup> International Congress of The European Society of Cardiovascular and Endovascular Surgery – ESCVS, 2012, Dubrovnik, Croatia (Faculty member, Presenter).
- 49) EUROPCR, May 2012, Paris, France (Faculty Member, Presenter)
- 50) The 1<sup>st</sup> International Heart Valve Summit of the Israel Heart Society, May 2012, Jerusalem, Israel (Organizing Committee)
- 51) Horizons in Invasive Cardiology, 2012, Rambam Medical Center, Haifa, Israel (Panelist)
- 52) ESC Congress, August 2012, Munich, Germany (Secretary General of IHS, Abstract Presenter)
- 53) Transcatheter Cardiovascular Therapeutics (TCT), October 2012, Miami, FL, USA (Faculty Member, Panelist, Reviewer of abstracts)
- 54) Innovations in Cardiovascular Interventions (ICI), December 2012, Tel-Aviv, Israel (Faculty member, scientific committee, abstract reviewer, panelist, Presenter)
- 55) American College of Cardiology (ACC.13), Annual Scientific Sessions, March 2013, San Francisco, CA, USA (Faculty member, Presenter, Panelist)

## **E. ACADEMIC AND PROFESSIONAL AWARDS**

- 1) Ranked the 1<sup>st</sup> in a sociometric evaluation survey among all officers in Barak Brigade Central Command ( $\approx$ 40 officers), Israeli Defense Forces (IDF) – 1993
- 2) Under my command, Golan Heights Medical Center was awarded as the best clinic in the Israeli Defense Forces (IDF) – 1995
- 3) Ranked the 1<sup>st</sup> in a sociometric evaluation survey among all officers in the 541 Medical Unit of the Northern Command ( $\approx$ 50 officers), Israeli Defense Forces (IDF) - 1995
- 4) Meir Hospital General Manager Award for a best residency research (3000 US\$) – November 1998

- 5) **Yael Foundation Research Grant, Israel.** Principal Investigator. Inhibition of vascular smooth muscle cell proliferation by a novel class of fibroblast growth factor receptor antagonists. (50,000 US\$) – December 1998 – November 2000.
- 6) Awarded as best teacher by 4-6<sup>th</sup> year medical students, Meir Hospital, Tel-Aviv University, 2001/2
- 7) **Merck, Sharp & Dome (MSD) Fellowship Award** – Israel Heart Society (10,000 US\$) – April 2002
- 8) “Reut” Foundation Fellowship Grant, Israel (10,000US\$) – September 2002
- 9) **Heart and Stroke Foundation of Canada Research Fellowship Award**, the role of adventitial angiogenesis in the arterial response to injury – (50,000 CA\$/year) – July 2003 – December 2004
- 10) **Department of Medicine - University of Toronto Research Award, Canada** (20,000 CA\$/year) – 2003/4
- 11) **The Edie Steinberg Scholarship Fund, Edward Christie Stevens Fellowship and the Nellie L. Farthing Fellowship**, Postgraduate Medicine Awards Committee of the Faculty of Medicine, University of Toronto, Ontario, Canada (6,950 CA\$) – 2003/4.
- 12) Finalist in a poster competition in clinical sciences. American Heart Association (AHA), 76<sup>th</sup> Scientific Sessions, Nov 2003, Orlando, FL, USA.
- 13) Best Abstract Award winner (1000US\$), 5<sup>th</sup> International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, Dec 2003, Tel-Aviv, Israel.
- 14) Kachel E, Kassif Y, Raanani E, Strauss BH, **Segev A.** Positive Remodeling in Venous Bypass Grafts: Novel Implications for Vein Graft Disease. **Ami Cohen Award Finalist.** The 54<sup>th</sup> Annual Meeting of The Israel Heart Society, 2007, Tel-Aviv, Israel
- 15) Amsalem Y, Guetta V, Laish-Farkash A, **Segev A.** Comparison of Late versus Early Stent Thrombosis: 5-Year Experience from a Large Unselected Population. Elad Grenadier Memorial Best Abstract Award. Horizons in Interventional Cardiology, 2008, Haifa, Israel

- 16) **Best Tutor in Cardiology - 2008**, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 17) **Segev A**, Nili N, Osheov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH. A Perlecan-Inducing Compound Significantly Inhibits Smooth Muscle Cell Function and In-stent Intimal Hyperplasia - Novel Insights into the Diverse Biological Effects of Perlecan. **Awarded as 5 of the best publications of the year in EuroIntervention**. Presented at EUROPCR, Paris, France. May 2010
- 18) Cardiovascular Research Technologies (CRT) **Young Leadership Program Award**. Washington, DC, USA. February 2011.
- 19) Goldenberg G, **Segev A**, Dvir D, Kornowski R, Finkelstein A, Hay I, Glikson M, Guetta V. Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve revalving system. Elad Grenadier Memorial Best Abstract Award. Horizons in Interventional Cardiology, 2011, Haifa, Israel
- 20) **Best Teacher in Cardiology - 2011**, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

#### **F. MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

- 1) Israel Medical Association
- 2) Israel Heart Society – Secretary General (2011-present)
- 3) The College of Physicians and Surgeons of Ontario (CPSO) (2002-2004)
- 4) Canadian Cardiovascular Society (CCS) (2002-2004)
- 5) The Society of Cardiovascular Angiography and Interventions (SCAI)
- 6) American Heart Association (AHA) – Arteriosclerosis, Thrombosis & Vascular Biology Council
- 7) European Association of Percutaneous Cardiovascular Interventions (EAPCI) 8) FESC – Fellow of the European Society of Cardiology

## **SCIENTIFIC PUBLICATIONS**

### **PEER-REVIEWED PAPERS:**

#### **B.1. ORIGINAL ARTICLES - PUBLISHED:**

- 1) Aviezer D, Cotton S, David M, **Segev A**, Khaselev N, Galili N, Gross Z, Yayon A. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression and metastases.

*Cancer Res* 2000, 60:2973-2980 (*ONCOLOGY 12/194, IF 7.856*)

- 2) Niv E, **Segev A**, Ellis MH.

Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura.

*Transfusion* 2000, 40:1067-70 (*HEMATOLOGY 26/68, IF 3.217*)

- 3) **Segev A**, Aviezer D, Safran M, Gross Z, Yayon A.

Inhibition of vascular smooth muscle cell proliferation by a novel class of fibroblast growth factor receptor antagonist.

*Cardiovasc Res* 2002, 53:232-241 (*CARDIAC & CARDIOVASCULAR SYSTEMS 13/117, IF 6.064*)

- 4) Strauss BH, Goldman L, Qiang B, Nili N, **Segev A**, Butany J, Sparkes JD, Jackson ZS, Eskandarian MR, Virmani R.

Collagenase plaque digestion for facilitating guidewire crossing in chronic total arterial occlusions.

*Circulation* 2003, 108:1259-1262 (*CARDIAC & CARDIOVASCULAR SYSTEMS 1/117, IF 14.739*)

- 5) Lau HK, **Segev A**\*, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Thrombin-activatable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic coronary restenosis.

*Thromb Haemost* 2003, 60:1217-1221. \***First two authors contributed equally**  
(**HEMATOLOGY 10/68, IF 5.044**)

6) Daoulah A, **Segev A**, Leblanc K, Chisholm RJ, Strauss BH.

Post-procedural low molecular weight heparin in patients at high risk of subacute stent thrombosis.

*Cardiovasc Radiat Med* 2003, 4:182-185. (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

7) **Segev A**, Kassam S, Buller CE, Lau HK, Sparkes JD, Seidelin PH, Natarajan MK, Cohen EA, Strauss BH.

Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after stenting.

*Eur Heart J* 2004, 25:1029-35. (**CARDIAC & CARDIOVASCULAR SYSTEMS 3/114, IF 10.478**)

8) **Segev A**, Cantor WJ, Cohen EA, Seidelin PH, Natarajan MK, Marquis JF, Lazzam C, Watson RK, Chisholm RJ, Strauss BH.

Low rates of angiographic and clinical restenosis with the new flexible MedStent for the treatment of single discrete coronary lesions.

*J Interven Cardiol* 2004, 17:167-170. (**CARDIAC & CARDIOVASCULAR SYSTEMS, 88/117, IF 1.185**)

9) Tsimikas S, Lau HK, Han KR, Shortal B, Miller E, **Segev A**, Curtiss LK, Witztum JL, Strauss BH.

Percutaneous coronary intervention results in acute increases in oxidized phospholipids and Lp(a): acute and long-term immunological responses to oxidized LDL.

*Circulation*, 2004, 109:3164-70. (**CARDIAC & CARDIOVASCULAR SYSTEMS 1/117, IF 14.739**)

10) Qiang B, **Segev A**, Beliard I, Nili N, Strauss BH, Sefton MV.

Poly(methylidene malonate 2.1.2) nanoparticles: a biocompatible polymer that enhances peri-adventitial adenoviral gene delivery.

*J Control Release*, 2004, 98:447-455. (**PHARMACOLOGY & PHARMACY 15/261, IF 5.732**)

11) **Segev A**, Goldman LE, Cantor WJ, Barr A, Strauss BH, Winegard LD, Bowman KA, Chisholm RJ.

Elevated troponin-I after percutaneous coronary interventions: incidence and risk factors.

*Cardiovasc Radiat Med* 2004, 5:59-63. (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

12) **Segev A**, Hegele RA, Lau HK, Sparkes JD, Chisholm RJ, Strauss BH.

Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. *Thromb Res* 2004, 114:135-139. (**HEMATOLOGY 39/68, IF 2.440**)

13) Segev F, Mor O, **Segev A**, Belkin M, Assia EI.

Downregulation of gene expression in the ageing lens: a possible contributory factor in senile cataract.

*Eye* 2005, 19:80-5. (**OPHTHALMOLOGY 23/58, IF 1.851**)

14) **Segev A**, Ellis MH, Segev F, Friedman Z, Reshef T, Tetro J, Pauzner H, David D.

High prevalence of thrombophilia markers among young patients with myocardial infarction and few conventional risk factors.

*Int J Cardiol* 2005, 98:421-424. (**CARDIAC & CARDIOVASCULAR SYSTEMS 7/117, IF 7.078**)

15) **Segev A**, Strauss BH, Tan M, Constance C, Langer A, Goodman SG.

Predictors and long-term outcome of major bleeding in patients with non-ST elevation acute coronary syndromes: insights from the Canadian Acute Coronary

Syndrome Registries.

*Am Heart J* 2005, 150:690-694. (**CARDIAC & CARDIOVASCULAR SYSTEMS 21/117, IF 4.651**)

16) **Segev A**, Strauss BH, Witztum JL, Lau HK, Tsimikas S.

Relationship of a comprehensive panel of plasma OxLDL markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina.

*Am Heart J* 2005, 150:1008-1015. (**CARDIAC & CARDIOVASCULAR SYSTEMS 21/117, IF 4.651**)

17) **Segev A**, Nili N, Qiang B, Charron T, Butany J, Strauss BH.

Human-grade purified collagenase for the treatment of experimental chronic total occlusions.

*Cardiovasc Revasc Med* 2005, 6:65-69. (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

18) Cheema AN, Hong T, Nili N, **Segev A**, Moffat JG, Lipson KE, Howlett AR, Holdsworth DW, Cole M, Qiang B, Kolodgie F, Virmani R, Stewart DJ, Strauss BH. Adventitial angiogenesis: a novel mechanism of in-stent restenosis and inhibitory effects of SU11218, a tyrosine kinase inhibitor.

*J Am Coll Cardiol* 2006;47:1067-75. (**CARDIAC & CARDIOVASCULAR SYSTEMS 2/117, IF 14.156**)

19) Strauss BH, **Segev A**, Wright GA, Qiang B, Munce N, Anderson KJT, Leung G, Dick AJ, Virmani R, Butany J.

Microvessels in chronic total occlusions: pathway for successful guide-wire crossing?

*J Intervent Cardiol* 2005;18:425-36. (**CARDIAC & CARDIOVASCULAR SYSTEMS, 88/117, IF 1.185**)

20) Elian D, Guetta V, Alcalai R, Lotan C, **Segev A.**

Early mobilization after diagnostic cardiac catheterization with the use of a hemostatic bandage containing thrombin.

*Cardiovasc Revasc Med* 2006;7:61-3. (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

21) **Segev A.**, Strauss BH, Tan M, Mendelsohn AA, Lai K, Ashton T, Fitchett D, Grima E, Langer A, Goodman SG.

Prognostic significance of admission heart failure in patients with non ST-elevation acute coronary syndrome - from the Canadian Acute Coronary Syndrome Registries.

*Am J Cardiol* 2006; 98:45-48. (**CARDIAC & CARDIOVASCULAR SYSTEMS 33/117, IF 3.368**)

22) **Segev A.**, Cantor WJ, Strauss BH.

Outcome of percutaneous coronary interventions in HIV-infected patients

*Catheter Cardiovasc Interv* 2006;86:879-81. (**CARDIAC & CARDIOVASCULAR SYSTEMS 54/117, IF 2.290**)

23) **Segev A.**, Strauss BH, Tan M, Buller CE, Mendelsohn AA, Langer A, Goodman SG.

Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndrome.

*Int J Cardiol* 2008;129:233-7 (**CARDIAC & CARDIOVASCULAR SYSTEMS 7/117, IF 7.078**)

24) **Segev A.**, Elian D, Marai I, Matetzky S, Agranat O, Har-Zahav Y, Guetta V. Thrombus aspiration during primary percutaneous coronary intervention in acute STElevation myocardial infarction.

*Cardiovasc Revasc Med* 2008;9:140-3. (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

25) Fefer P, Hod H, Ilany J, Shechter M, **Segev A**, Novikov I, Guetta V, Matetzky S. Comparison of myocardial reperfusion in patients with fasting blood glucose < or =100, 101 to 125, and >125 mg/dl and ST-elevation myocardial infarction with percutaneous coronary intervention.

*Am J Cardiol* 2008;102:1457-62. (**CARDIAC & CARDIOVASCULAR SYSTEMS 33/117, IF 3.368**)

26) Parikh KH, Shah A, Chag MC, **Segev A**.

Ovalum CiTop™ Expander™: A novel guidewire for crossing coronary chronic total occlusions – First-in-Man experience.

*EuroIntervention* 2009;5:206-11. (**CARDIAC & CARDIOVASCULAR SYSTEMS 36/117, IF 3.285**)

27) **Segev A**, Fefer P, Strauss BH, Matetzky S, Tan M, Langer A, Goodman SG.

Outcome of patients with acute coronary syndromes enrolled in clinical trials.

*Cor Art Dis* 2009;20(7):473-476. (**PERIPHERAL VASCULAR DISEASE, 40/68, IF 1.665**)

28) Fefer P, Hod H, Hammerman H, **Segev A**, Beinart R, Boyko V, Behar S, Matetzky S.

Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.

*Am J Cardiol* 2009;104(4):514-8. (**CARDIAC & CARDIOVASCULAR SYSTEMS 33/117, IF 3.368**)

---

29) **Segev A**, Nili N, Osherov AB, Qiang B, Wong AJ, Pillarisetti R, Strauss BH.

Perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia - novel insights into the diverse biological effects of perlecan.

*EuroIntervention* 2010;6(1):134-40. (**CARDIAC & CARDIOVASCULAR SYSTEMS 36/117, IF 3.285**)

30) Beinart R, Abu Sham'a R, **Segev A**, Hod H, Guetta V, Shechter M, Boyko V, Behar S, Matetzky S.

The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome.

*Am Heart J* 2010;159(1):118-24. (**CARDIAC & CARDIOVASCULAR SYSTEMS 21/117, IF 4.651**)

31) Danenberg H, Finkelstein A, Kornowski R, **Segev A**, Dvir D, Gilon D, Keren G, Sagie A, Feinberg M, Schwammenthal E, Banai S, Lotan C, Guetta V.

Percutaneous implantation of the self-expandable CoreValve for high-risk patients with severe aortic valve stenosis: early Israeli experience.

*Isr Med Assoc J* 2010;12:468-471. (**MEDICINE, GENERAL & INTERNAL 81/153, IF 1.018**)

32) Fefer P, Daoulah A, Strauss BH, Chisholm RJ, Sparkes JD, **Segev A**.  
Visible angiographic complications predict short and long-term outcomes in patients with post-procedural creatine-phosphokinase elevation.

*Catheter Cardiovasc Interv* 2010;76:960-6 (**CARDIAC & CARDIOVASCULAR SYSTEMS 54/117, IF 2.290**)

33) Charron T, Jaffe R, **Segev A**, Bang KWA, Qiang B, Sparkes JD, Butany J, Dick AJ, Freedman J, Strauss BH.

Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow.

*Thromb Res* 2010;126:50-55 (**HEMATOLOGY 39/68, IF 2.440**)

- 34) **Segev A**, Nili N, Qiang B, Osherov AB, Giordano F, Jaffe R, Gauldie J, Sparkes JD, Fraser AR, Ladouceur-Wodzak M, Butany J, Strauss BH.

Inhibition of neo-intimal hyperplasia after stenting by over-expression of p15 – a member of the INK4 family of CDK inhibitors.

*J Mol Cell Cardiol* 2011;50:417-25 (**CARDIAC & CARDIOVASCULAR SYSTEMS** 17/117, **IF 5.166**)

- 35) Hamdan A, Guetta V, Konen E, Goitein O, **Segev A**, Raanani E, Spiegelstein D, Hay I, DiSegni E, Eldar M, Schwammenthal E.

Deformation dynamics and mechanical properties of the aortic annulus by fourdimensional computed tomography - Insights into the functional anatomy of the aortic valve complex and implications for transcatheter aortic valve therapy.

*J Am Coll Cardiol* 2012;59:119-27 (**CARDIAC & CARDIOVASCULAR SYSTEMS** 2/117, **IF 14.156**)

- 36) Guetta V, Goldenberg G, **Segev A**, Dvir D, Kornowski R, Finkelstein A, Hay I, Goldenberg I, Glikson M.

Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve revalving system.

*Am J Cardiol* 2011;108:166-5. (**CARDIAC & CARDIOVASCULAR SYSTEMS** 33/117, **IF 3.368**)

- 37) Fefer P, Tsimikas S, **Segev A**, Lau H, Sparkes J, Otsuma F, Kolodgie F, Virmani R, Charron T, Strauss BH.

The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries following successful percutaneous revascularization.

*Cardiovasc Revasc Med*, 2011;13:11-9 (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

- 38) **Segev A**, Beigel R, Goitein O, Brosh S, Oiero D, Konen E, Hod H, Matetzky S. Non-significant coronary artery disease upon multi-detector computed tomography in patients presenting with acute chest pain - Results of an intermediate term follow-up.

*Eur Heart J Cardiovasc Imaging*, 2012;13:169-73 (**CARDIAC & CARDIOVASCULAR SYSTEMS 53/117, IF 2.317**)

- 39) Jaffe R, Finkelstein A, Lewis BS, Guetta V, Khader N, Halon DA, **Segev A**. Stenting of the unprotected left main coronary artery in patients with severe aortic stenosis prior to percutaneous valve interventions

*Cardiovasc Revasc Med*, 2012;13:90-4 (**CARDIAC & CARDIOVASCULAR SYSTEMS, not listed**)

- 40) **Segev A**, Spiegelstein D, Fefer P, Shinfeld A, Hay I, Raanani E, Guetta V  
Trans-catheter aortic valve implantation for non-classical indications.

*Isr Med Assoc J* 2012, in-press (**MEDICINE, GENERAL & INTERNAL 81/153, IF 1.018**)

- 41) **Segev A**, Matetzky S, Danenberg H, Buby L, Zahger D, Roguin A, Gottlieb S, Kornowski R; for the ACSIS and ACSIS-PCI 2010 investigators

Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: Insights from 2010 ACSIS and ACSIS-PCI

Registries.

*EuroIntervention*, 2012;8:465-9 (**CARDIAC & CARDIOVASCULAR SYSTEMS 36/117, IF 3.285**)

- 42) Ben-Dov I, Kogan A, Preisman S, Rimon U, **Segev A**, Schafers JH.

Chronic thromboembolic pulmonary hypertension: can successful thrombendarterectomy normalize exercise capacity and gas exchange?

*Harefuah*, 2012;151:74-8.

- 43) Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F, Moat NE, Testa L, Hengstenberg C, Bekeredjian R, Lefevre T, Guetta V, Nissen H, Hernández JM, Roy D, Teles R, **Segev A**, Dumonteil N, Fiorina C, Gotzmann M, Tchetché D, Abdel-Wahab M, De Marco F, Baumbach A, Laborde JC, Kornowski R.

Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Results from the Global Valve-in-Valve Registry.

*Circulation*, 2012;126: 2335-44 (**CARDIAC & CARDIOVASCULAR SYSTEMS 1/117, IF 14.739**)

- 44) Fefer P, Gannot S, Lubetsky A, Martinowitz U, Matetzky S, Guetta V, **Segev A**  
Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome – An interventional dilemma: case Series, review of the literature, and tips for management.

*J Thromb Thrombolys*, 2012;in-press (**HEMATOLOGY 50/68, IF 1.476**)

- 45) Beigel R, Brosh S, Goitein O, Guttman E, Novikov I, **Segev A**, Oieru D, Gerber Y, Konen E, Hod H, Matetzky S

Prognostic Implications of Non-obstructive Coronary Artery Disease in Patients Undergoing Coronary Computed Tomography Angiography for Acute Chest Pain.

*Am J Cardiol* in-press. (**CARDIAC & CARDIOVASCULAR SYSTEMS 33/117, IF 3.368**)

### **B.1. ORIGINAL ARTICLES – SUBMITTED / IN PREPERATION:**

- 1) Buber Y, Laish- Farkash A, Koren M, Fefer P, **Segev A**, Dulman R, Hod H, Matetzky S. The pattern of cardiac troponin elevation in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction and its implications for patients' outcomes.

- 2) Rozen G, Fefer P, Shinfeld A, Sternik L, Guetta V, Malachy A, Levin S, Feinberg M, Raanani E, **Segev A**.

Surgical Aortic Valve Replacement for Severe Aortic Stenosis in the Era of Transcatheter Implantation

- 3) Moriel M, Matetsky S, **Segev A**, Kornowski R, Danenberg H, Buby L, Goldenberg I, Tzivoni D, Gottlieb S.

Thrombus aspiration in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention - Insights from the Acute Coronary Syndrome Israeli Survey 2010.

- 5) Beigel R, Matetzky S, Fefer P, Danenberg H, Gottlieb S, Zahger D, Goldenberg I, Kornowski R, **Segev A**

High-risk angiographic findings in patients with non ST-elevation acute coronary syndrome are predicted by clinical parameters and not by cardiac biomarkers

- 6) Beigel R, Fefer P, Rosenberg N, Novikov I, Elian D, Fink N, **Segev A**, Guetta V, Hod H, Matetzky S. The anti-platelet effect of thienopyridine pre-treatment in patients undergoing primary percutaneous angioplasty for ST-elevation myocardial infarction.

- 6) Fefer P, Matetzky S, Kornowski R, Danenberg H, Gottlieb S, Zahger D, Finkelstein A, Goldenberg I, **Segev A**.

Radial versus femoral access for intervention in patients with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS) 2010.

- 7) Orvin K, Gottlieb S, Goldenberg I, Matetzky S, Golovchiner G, Kuznietz J, Buby L, Battler A, Kornowski R, **Segev A**, Strasberg B, Haim M.

Outcome of contemporary acute myocardial infarction patients complicated by ventricular tachycardia and ventricular fibrillation.

## **B.2. CASE REPORTS – PUBLISHED**

- 1) **Segev A**, Ben-Chetrit S, Orion Y, Segev F, Bernhheim J, Bernheim J, Mekori YA.  
Acute eosinophilic interstitial nephritis and uveitis (TINU Syndrome) associated with granulomatous hepatitis.

*Clin Nephrology* 1999, 51:310-3

- 2) **Segev A**, Manor Y, Bernheim J, Mekori YA.

Light chain myeloma presenting as severe obstructive jaundice from hepatic amyloidosis.

*Eur J Haematol* 1999, 63:364-365

- 3) Mor A, **Segev A**, Hershkoviz R, Mekori YA.

Hypereosinophilic syndrome presenting as acute myocardial infarction.

*Allergy* 2000, 55:899-900

- 4) Mor A, **Segev A**, Hershkoviz R, Mekori YA.

Thallium scan and pulmonary carcinoma.

*Harefuah* 2000, 138:831-833 (Hebrew)

- 5) **Segev A**, Hadari R, Zehavi T, Hershkoviz R, Schneider M, Mekori YA.

Lupus-like syndrome with sub-massive hepatic necrosis associated with hepatitis A. *J*

*Gastroenterol Hepatol* 2001, 16:112-4

- 6) Segev F, **Segev A**, Livne A, Assia EI, Mekori YA.

Bilateral central retinal vein occlusion in a patient with occult colon cancer.

*Arch Ophthalmol* 2001, 119:1552-3

- 7) **Segev A**, Strauss BH, Coates J, Freeman MR, Gallo R.

Endocardial cryotherapy as a novel strategy of improving myocardial perfusion in a patient with severe coronary artery disease.

*Catheter Cardiovasc Interv* 2003, 60:229-232.

### **B.3. REVIEWS – PUBLISHED:**

1) **Segev A**, Nili N, Strauss BH.

The role of perlecan in arterial injury and angiogenesis.

*Cardiovasc Res* 2004, 63:603-610.

2) **Segev A**, Strauss BH.

Novel approaches for the treatment of chronic total coronary occlusions.

*J Interven Cardiol*, 2004, 17:411-416.

### **C. CHAPTERS IN BOOKS:**

1) **Segev A**, Sierevogel MJ, Pasterkamp G, Strauss BH.

The Role of Matrix Metalloproteinases Inhibitors after Arterial Injury. In: de Scheerder I, Camenzind E (editors). Local Drug Delivery for Coronary Artery Disease. Established and Emerging applications. Taylor & Francis, A Martin Dunitz

Publishing, London. 2005; chapter 26, pp 229-237

### **D1. INVITED PAPERS IN INTERNATIONAL SCIENTIFIC MEETINGS**

1) **Segev A**. Plaque digestion with collagenase: an alternative treatment strategy for chronic total occlusions. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. Oct 2004.

2) **Segev A**. Perlecan inducers: a novel approach for drug-eluting stents. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. Oct 2004.

3) **Segev A**. Interventional ‘digestion’ of chronic total occlusions. GCI – Global Cardiovascular Interventions, Frankfurt, Germany. Nov 2004

- 4) **Segev A.** Chronic Total Occlusions: Exploring the Final Fronteir. Pharmacologic Dissolution: Collagenase. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. October 2005.
- 5) **Segev A.** Technical strategies in CTO revascularization. 1<sup>st</sup> Israeli Chronjc Total Occlusion Meeting. Jerusalem, Israel. May 2007
- 6) **Segev A.** Primary PCI in SVG occlusion. EUROPCR, Barcelona, Spain. May 2007
- 7) **Segev A.** FIM Multicenter Randomized Study: The Ovalum CiTop™ Guidewire System for Recanalization of Peripheral CTOs. EuroPCR, Barcelona, Spain. May 2008
- 8) **Segev A.** FIM Study: The Ovalum CiTop™ Expander™ Guidewire for Recanalization of Coronary CTOs. EuroPCR, May 2009, Barcelona, Spain
- 9) **Segev A.** The role of thrombus aspiration in patients undergoing primary PCI. Montreal Interventional Cardiology Meeting, Montreal, Canada, June 2009
- 10) **Segev A.** The Ovalum CiTop™ Guidewire for recanalization of chronic total occlusion. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. September 2009
- 11) **Segev A.** Therapeutic options for late drug-eluting stents failure. 6th International Meeting on Intensive Cardiac Care, Tel-Aviv, Israel, October 2009
- 12) **Segev A.** Primary PCI in patients with multi-vessel disease  
Beyond the culprit lesion? EuroPCR, May 2010, Paris, France.
- 13) **Segev A.** A Perlecan-Inducing Compound Significantly Inhibits Smooth Muscle Cell Function and In-stent Intimal Hyperplasia - Novel Insights into the Diverse Biological Effects of Perlecan. EuroPCR, May 2010, Paris, France
- 14) **Segev A.** The Ovalum CiTop Guidewire: Device Evolution, Peripheral, and Coronary Applications. 7<sup>th</sup> International Chronic Total Occlusion Summit, New York, NY, USA. February 2010
- 15) **Segev A.** My most challenging cases. Simultaneous primary PCI during CPR and systemic cooling. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010

- 16) **Segev A.** Meeting the experts. Presentation of complex cases of transcatheter aortic valve implantation (TAVI). Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010
- 17) **Segev A.** The Ovalum CiTop™ 0.014 guide-wire – device evolution and coronary and peripheral application. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010
- 18) **Segev A.** Interventional management of ACS in 2010. The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.
- 19) **Segev A.** Transcatheter Aortic Valve Implantation: Patient selection and strategies for optimal outcomes. International Summit on Imaging and Intervention in Cardiology (ISIIC), September 2011, Katowice, Poland
- 20) **Segev A.** The remaining unmet needs in coronary interventions. Innovations in Cardiovascular Interventions (ICI), December 2011, Tel Aviv, Israel
- 21) **Segev A.** Strategies to reduce major bleeding in patients with ACS undergoing PCI. American College of Cardiology (ACC.12) Scientific Sessions, 2012, Chicago, IL, USA
- 22) **Segev A.** My Experience with Trans-femoral TAVI. The 61<sup>st</sup> International Congress of The European Society of Cardiovascular and Endovascular Surgery – ESCVS, 2012, Dubrovnik, Croatia
- 23) **Segev A.** The unmet needs in coronary interventions. Innovations in Cardiovascular Interventions (ICI), December 2012, Tel Aviv, Israel
- 24) **Segev A.** CTO 2013 – still an open issue? Innovations in Cardiovascular Interventions (ICI), December 2012, Tel Aviv, Israel
- 25) **Segev A.** Revisiting Coronary Stent Engineering: Evolution of BioMime & Advancement to Aura, Morph & Mitsu. Innovations in Cardiovascular Interventions (ICI), December 2012, Tel Aviv, Israel
- 26)
- 27)

**D.2. PAPERS PRESENTED IN INTERNATIONAL SCIENTIFIC MEETINGS  
PUBLISHED AS ABSTRACTS:**

- 1) **Segev A**, Aviezer D, Gross Z, Yayon A. Inhibition of Vascular Smooth Muscle Cell Proliferation by a Novel Class of Fibroblast Growth Factor Antagonists. American Heart Association (AHA), 71<sup>st</sup> Scientific Sessions, 1998, Dallas, TX, USA. *Circulation* 1998:
  
- 2) Lau HK, **Segev A**, Sparkes JA, Teitel JM, Chisholm RJ, Strauss BH. Thrombin-activable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic coronary restenosis. American Heart Association (AHA), 75<sup>th</sup> Scientific Sessions, 2002, Chicago, IL, USA. *Circulation* 2002:
  
- 3) **Segev A**, Kassam S, Buller CE, Lau HK, Sparkes JD, Seidelin PH, Natarajen MK, Cohen EA, Strauss BH. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after stenting. Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada. *Can J Cardiol* 2003;19(Suppl A):136A
  
- 4) **Segev A**, Lau HK, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Thrombin-activatable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic coronary restenosis. Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada. *Can J Cardiol* 2003;19(Suppl A):189A
  
- 5) **Segev A**, Goldman L, Qiang B, Nili N, Butany J, Sparkes JD, Jackson ZS, Eskandarian MR, Virmani R, Strauss BH. Collagenase plaque digestion for facilitating guidewire crossing in chronic total arterial occlusions. Canadian Cardiovascular Society Congress (CCSC), 2003, Toronto, ON, Canada. *Can J Cardiol* 2003;19(Suppl A):170A
  
- 6) **Segev A**, Ellis MH, Segev F, Friedman Z, Reshef T, Pauzner H, David D. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. American Heart Association

(AHA), 76<sup>th</sup> Scientific Sessions, 2003, Orlando, FL, USA. *Circulation* 2003:  
**Finalist in poster competition in clinical sciences.**

- 7) **Segev A**, Kassam S, Buller CE, Lau HK, Sparkes JD, Seidelin PH, Natarajen MK, Cohen EA, Strauss BH. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after stenting. American College of Cardiology (ACC), 53<sup>rd</sup> Annual Scientific Sessions, 2004, New Orleans, LA, USA. *J Am Coll Cardiol* 2004
- 8) **Segev A**, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. Predictors and one-year outcome of major bleeding in patients with non-ST elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. American Heart Association (AHA), 77<sup>th</sup> Scientific Sessions, 2004, New Orleans, LA, USA.
- 9) **Segev A**, Nili N, Qiang B, Wong A, Pasterkamp G, Pillarisetti S, Virmani R, Strauss BH. Stents coated with a perlecan-inducing compound significantly reduce intimal hyperplasia in a rabbit iliac in-stent restenosis model - novel insights into the diverse biological effects of perlecan. American Heart Association (AHA), 77<sup>th</sup> Scientific Sessions, 2004, New Orleans, LA, USA.
- 10) Burstein JM, **Segev A**, Strauss BH, Cheema A, Cantor WJ, Kutryk MB, Charron T, Sheth T, Chisholm RJ. Stenting of bifurcation lesions using drug eluting stents. Canadian Cardiovascular Society Congress (CCSC), 2005, Montreal, QB, Canada. *Can J Cardiol* 2005:
- 11) Charron T, Bang A, Qiang B, Puley G, **Segev A**, Shakoor S, Freedman J, Strauss BH. No-Reflow after coronary distal embolization: role of platelet activation and interactions between platelets and white blood cells. Canadian Cardiovascular Society Congress (CCSC), 2005, Montreal, QB, Canada. *Can J Cardiol* 2005

- 12) **Segev A**, Elian D, Matetzky S, Guetta V. Thrombus aspiration during primary percutaneous coronary intervention in acute ST-elevation myocardial infarction. 9<sup>th</sup> International Congress on Coronary Artery Disease (ICCAD), October 2009, Prague, Czech Republic.
  
- 13) **Segev A**. The Ovalum CiTop™ Guidewire for recanalization of chronic total occlusion. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. September 2009
  
- 14) **Segev A**. Primary PCI in patients with multi-vessel disease Beyond the culprit lesion? EUROPCR, Paris, France. May 2010
  
- 15) **Segev A**, Nili N, Osheov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH. A Perlecan-Inducing Compound Significantly Inhibits Smooth Muscle Cell Function and In-stent Intimal Hyperplasia - Novel Insights into the Diverse Biological Effects of Perlecan. EUROPCR, Paris, France. May 2010
  
- 16) Beigel R, **Segev A**, Goitein O, Brosh S, Oieru D, Konen E, Asher E, Hod H, Matetzky S. Non obstructive coronary artery disease upon multidetector computed tomography in patients presenting with acute chest pain - Does it matter? European Society of Cardiology Congress, Stockholm, Sweden. 2010
  
- 17) Fink N, Kuperstein R, **Segev A**, Guetta V, Sternik L, Raanani E, Feinberg MS. Early and mid term hemodynamic profile of the percutaneous CoreValve™ compared to surgical bioprosthesis for the treatment of severe aortic stenosis – a single center experience. American College of Cardiology (ACC), 60<sup>th</sup> Annual Scientific Sessions, 2011, New Orleans, LA, USA. J Am Coll Cardiol  
2011
  
- 18) Buber Y, Laish- Farkash A, Koren M, Fefer P, **Segev A**, Dulman R, Hod H, Matetzky S. The Pattern of Cardiac Troponin Elevation in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial

- Infarction and its Implications for Patients' Outcomes. American College of Cardiology (ACC), 60<sup>th</sup> Annual Scientific Sessions, 2011, New Orleans, LA, USA. J Am Coll Cardiol 2011
- 19) Hamdan A, Guetta V, Konen E, Raanani E, **Segev A**, Spigelstein D, Hay I, Goitein O, Eldar M, Schwammenthal E. assessing aortic annular dynamics by four-dimensional multislice computed tomography: implications for transcatheter aortic valve implantation. European Society of Cardiology Congress, Paris, France, August 2011. Eur Heart J 2011
- 20) Dvir D, Laborde JC, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutures F, Moat NE, Hengstenberg C, Bekerdjian R, Lefevre T, Nissen H, Hernández JM, Roy D, De Marco F, Teles R, **Segev A**, Baumbach A, Dumonteil N, Fiorina C, Ioanes D, Napodano M, Tchetché D, Ussia GP, Merx MW, Abdel-Wahab M, Kornowski R. Transcatheter aortic-valve implantation for the treatment of degenerative bioprosthetic surgical valves: results from the Global VIV (Valve-in-Valve) Registry. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA. November 2011. J Am Coll Cardiol 2011
- 21) Hamdan A, Guetta V, Konen E, Goitein O, **Segev A**, Raanani E, Spiegelstein D, Hay I, DiSegni E, Eldar M, Schwammenthal E. Deformation dynamics and mechanical properties of the aortic annulus by four-dimensional computed tomography - insights into the functional anatomy of the aortic valve complex and implications for transcatheter aortic valve therapy. American Heart Association (AHA) Scientific Meeting, Orlando, FL, USA, November 2011. Circulation 2011
- 22) Beigel R, Brosh S, Goitein O, Gutman E, **Segev A**, Konen E, Oieru D, Hod H, Matetzky S. The significance of non-obstructive coronary artery disease upon multi-detector computed tomography in patients presenting with acute chest pain. American College of Cardiology (ACC.12) Scientific Sessions, 2012, Chicago, IL, USA. J Am Coll Cardiol 2012

- 23) Moriel M, Matetsky S, **Segev A**, Kornowski R, Danenberg H, Buby L, Goldenberg I, Tzivoni D, Gottlieb S. Thrombus aspiration in patients with STElevation myocardial infraction undergoing primary percutaneous coronary intervention - Insights from the Acute Coronary Syndrome Israeli Survey 2010. American College of Cardiology (ACC.12) Scientific Sessions, 2012, Chicago, IL, USA. J Am Coll Cardiol 2012
- 24) **Segev A**, Spiegelstein D, Fefer P, Shinfeld A, Hay I, Raanani E, Guetta V. Off-label use of trans-catheter aortic valve implantation. European Society of Cardiology Congress, Munich, Germany, August 2012. Eur Heart J 2012
- 25) Rozen G, Fefer P, Shinfeld A, Sternik L, Guetta V, Levin S, Malachy A, Raanani E, **Segev A**. Surgical aortic valve replacement for severe aortic stenosis in the era of transcatheter implantation. European Society of Cardiology Congress, Munich, Germany, August 2012. Eur Heart J 2012

### **D.3. OTHER ABSTRACTS IN SCIENTIFIC MEETINGS:**

- 1) **Segev A**, Barenboim E, Schneider M, Mekori YA.  
Light Chain Myeloma – 3 Different Aspects of a Rare Disease.  
Annual Meeting of the Israel Internal Medicine Society, 1998, Tel-Aviv, Israel
- 2) **Segev A**, Bental T, Rozenbaum E, Arbel J, Pauzner H, Bakst A, David D. Gender Differences in Mortality of Elderly Patients After Percutaneous Coronary Interventions.  
The 48<sup>th</sup> Annual Conference of the Israel Heart Society, 2001, Jerusalem, Israel
- 3) **Segev A**, Rozenbaum EA, Arbel J, Bental T, Bakst A, David D.  
Treatment of in-stent restenosis with excimer laser ablation and rotational atherectomy – Meir Hospital experience.  
The 48<sup>th</sup> Annual Conference of the Israel Heart Society, 2001, Jerusalem, Israel
- 4) Bental T, Arbel J, Rozenbaum EA, **Segev A**, Bakst A, David D.

Primary PCI – Meir Hospital experience.

The 48<sup>th</sup> Annual Conference of the Israel Heart Society, 2001, Jerusalem, Israel

5) **Segev A**, Behar S, Boyko V, David D.

The potential benefit of pre-event treatment with ACE inhibitors or beta-blockers in patients with acute myocardial infarction – data from the ARGAMI study.

The 49<sup>th</sup> Annual Conference of the Israel Heart Society, 2002, Tel-Aviv, Israel

6) **Segev A**, Ellis MH, Friedman Z, Reshef T, Pazner H, David D.

Hypercoagulability profile of young patients in the course of a first myocardial infarction.

The 49<sup>th</sup> Annual Conference of the Israel Heart Society, 2002, Tel-Aviv, Israel

7) **Segev A**, Chisholm RJ.

Saphenous vein graft perforation – case presentation – final challenging cases competition.

Transcatheter Cardiovascular Therapeutics (TCT), 2003, Washington, DC, USA

8) **Segev A**, Nili N, Qiang B, Wong A, Paterkamp G, Pillarisetti R, Strauss BH.

Stents coated with a perlecan inducing compound significantly reduce intimal hyperplasia in a rabbit iliac in-stent restenosis model. 5<sup>th</sup> International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, 2003, Tel-Aviv,

Israel

9) **Segev A**, Lau HK, Hegele RA, Sparkes JA, Teitel JM, Chisholm RJ, Strauss BH.

Thrombin-activable fibrinolysis inhibitor (TAFI): A novel predictor of angiographic coronary restenosis.

5<sup>th</sup> International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, 2003, Tel-Aviv, Israel. **Best Abstract Award winner (1000US\$)**

10) **Segev A**, Strauss BH, Tan M, Langer A, Goodman SG.

Admission Heart Failure in Patients with Non ST-Elevation Acute Coronary Syndromes: Predictors and Long-Term Outcome. The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

11) **Segev A**, Strauss BH, Tan M, Buller CE, Langer A, Goodman SG.

Risk Factors and Outcome of In-Hospital Ischemic Stroke in Patients with Non-ST Elevation Acute Coronary Syndromes.

The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

12) **Segev A**, Qiang B, Nili N, Giordano FJ, Strauss BH.

Inhibition of Neo-Intimal Hyperplasia after Stenting by Over-Expression of p15 – a Memeber of the INK4 Family of CDK Inhibitors.

The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

13) **Segev A**, Nili N, Qiang B, Pasterkamp G, Virmani R, Strauss BH.

Stents coated with a perlecan-inducing compound significantly reduce intimal hyperplasia in a rabbit iliac in-stent restenosis model - Novel insights into the diverse biological effects of perlecan.

The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

14) **Segev A**, Strauss BH, Tan M, Langer A, Goodman SG.

Predictors and One-Year Outcome of Major Bleeding in Patients with Non-ST Elevation Acute Coronary Syndromes: Insights from the Canadian Acute Coronary Syndrome Registries.

The 52nd Annual Meeting of The Israel Heart Society, 2005, Tel-Aviv, Israel.

15) **Segev A**, Matetzky S, Tan M, Elian D, Langer A, Goodman SG.

Outcome of Patients with Acute Coronary Syndromes Enrolled in Clinical Studies.

The 53<sup>rd</sup> Annual Meeting of The Israel Heart Society, 2006, Tel-Aviv, Israel.

- 16) **Segev A**, Matetzky S, Marai I, Elian D, Agranat O, Har-Zahav Y, DiSegni E, Rath S, Hod H, Guetta V.

Thrombus Aspiration during Primary Percutaneous Coronary Intervention in Acute ST-Elevation Myocardial Infarction.

The 53<sup>rd</sup> Annual Meeting of The Israel Heart Society, 2006, Tel-Aviv, Israel.

- 17) **Segev A**, Kachel E, Nili N, Raanani E, Strauss BH.

Positive Remodeling in Venous Bypass Grafts: Novel Implications for Vein Graft Disease.

The 53<sup>rd</sup> Annual Meeting of The Israel Heart Society, 2006, Tel-Aviv, Israel.

- 18) Kachel E, Kassif Y, Raanani E, Strauss BH, **Segev A**.

Positive Remodeling in Venous Bypass Grafts: Novel Implications for Vein Graft Disease. Ami Cohen Award Finalist.

The 54<sup>th</sup> Annual Meeting of The Israel Heart Society, 2007, Tel-Aviv, Israel.

- 19) Amsalem Y, Guetta V, Laish-Farkash A, **Segev A**.

Comparison of Late versus Early Stent Thrombosis: 5-Year Experience from a Large Unselected Population.

The 55<sup>th</sup> Annual Meeting of The Israel Heart Society, 2008, Tel-Aviv, Israel

- 20) Laish-Farkash A, Hod H, **Segev A**, Sela B, Amsalem Y, Michailidis A, Matetzky S.

The Value of Troponin-I Curve after Primary PCI for ST Elevation Myocardial Infarction.

The 55<sup>th</sup> Annual Meeting of The Israel Heart Society, 2008, Tel-Aviv, Israel

- 21) **Segev A**, Danenberg H, Schwammenthal E, Gilon D, Guetta V, Lotan C. Percutaneous Implantation of the Self-Expandable CoreValve in Patients with Severe Aortic Stenosis: The Technique.

The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel

22) Parikh K, Shah A, Chag M, Scheinowitz M, **Segev A.**

Ovalum CiTop™: A Novel Guidewire for crossing Chronic Total Occlusion in Coronary Artery Disease patients – First-in-Man Experience.

The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel

23) Belenky A, Litvin S, Scheinowitz M, **Segev A.**

The New 0.014” CiTop™ Guidewire for the Treatment of Chronic Total Occlusions in Peripheral Arteries: Results of the First-in-Man Randomized Clinical Study. The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel

24) Danenberg H, **Segev A.**, Schwammenthal E, Hod H, Zfat D, Gilon D, Lotan C, Guetta V.

Percutaneous Implantation of the Self-Expandable CoreValve for High-risk Patients with Severe Aortic Stenosis: Initial Israeli Experience.

The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel.

25) **Segev A.**, Fefer P, Dahulah A, Sparkes J, Chisholm R, Strauss BH.

Post-Percutaneous Coronary Intervention Creatine Kinase Elevation: An Angiographic Complication Predicts a Worse 1-Year Outcome.

The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel.

26) **Segev A.**, Schwammenthal Y, Orion D, Guetta V.

Carotid Stenting for "Restenosis" after Surgical Endarterectomy.

The 56<sup>th</sup> Annual Meeting of The Israel Heart Society, 2009, Tel-Aviv, Israel.

27) **Segev A.**, Guetta V.

Thrombus aspiration during primary percutaneous coronary intervention in acute STElevation myocardial infarction.

9<sup>th</sup> International Congress on Coronary Artery Disease (ICCAD), October 2009, Prague, Czech Republic.

28) Danenberg H, Finkelstein A, Kornowski R, **Segev A**, Dvir D, Gilon D, Keren G, Sagie A, Feinberg M, Schwammenthal E, Banai S, Lotan C, Guetta V.

Percutaneous Implantation of the Self-Expandable CoreValve for High-Risk Patients with Severe Aortic-Valve Stenosis: Early Israeli Experience.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

29) **Segev A**, Guetta V, Bloom A, Gerniak A, Lotan C, Danenberg H.

Peripheral Vascular Complications following Transcatheter Aortic Valve Implantation: New Challenges to the Interventional Cardiologist.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

30) **Segev A**, Gotlieb S, Atar S, Roth A, Nahir M, Mosseri M, Danenberg H, Kornowski R, Behar S.

Trends of Coronary Procedures among Patients with Acute Coronary Syndrome in Israel (ACSIS 2002-2008).

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

31) Fefer P, **Segev A**, Elian D, Yonash M, Har Zahav Y, Agranat O, Rath S, Guetta V.

Unprotected Left Main Stenting: An Israeli Perspective.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

32) Fefer P, **Segev A**, Tsimikas S, Strauss BH.

Oxidized Phospholipids and Lipoprotein(a) Response Following Successful Percutaneous Revascularization of Chronically Occluded Coronary Arteries.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

33) Fefer P, Chisholm R, Sparkes JD, Strauss BH, Guetta V, **Segev A**.

Visible Angiographic Complications Predict Short and Long-Term Outcomes in Patients with Post-Procedural Creatine-Phosphokinase Elevation.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

34) **Segev A**, Schwammenthal I, Orion D, Tsabari R, Tanne D, Guetta V.  
Carotid Artery Stenting: Evaluation of a Neurology-Cardiology Team Approach.

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

35) Beigel R, **Segev A**, Goitein O, Brosh S, Oieru D, Konen E, Asher E, Hod H, Matetzky S.

Non Obstructive Coronary Artery Disease upon Multidetector Computed Tomography in Patients Presenting with Acute Chest Pain - Does it Matter?

The 57<sup>th</sup> Annual Meeting of The Israel Heart Society, 2010, Tel-Aviv, Israel.

36) Buber Y, Laish-Farkash A, **Segev A**, Fefer P, Koren-Morag N, Eldar M, Hod H, Matetzki S.

Clinical Implications of cTnI Elevation Curve following Primary Percutaneous Coronary Intervention.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

37) Hamdan A, Guetta V, konen E, Raanani E, **Segev A**, Goitein O, Spiegelstein D, Hay I, Eldar M, Schwammenthal E.

Assessing aortic annular dynamics by four-dimensional multislice CT: Implications for TAVI.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

38) Goldenberg G, **Segev A**, Dvir D, Kusneic H, Hay I, Finkelstein A, Kornowski R, Glikson M, Guetta V.

Predictors of atrio-ventricular conduction abnormalities requiring permanent pacemaker after TAVI.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

- 39) Fink N, Kuperstein R, Segev A, Guetta V, Sternik L, Raanani E, Feinberg MS. Hemodynamic profile of the percutaneous Corevalve™ compared to surgical aortic valve replacement.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

- 40) Jaffe R, Lewis BS, Guetta V, Khader N, Halon D, Segev A. Unprotected left main coronary artery stenting in high-risk patients with severe aortic stenosis.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

- 41) Asher E, Matetzky S, Fink N, Naimushin A, DiSegni E, Hod H, Agranat O, Guetta V, Har-Zahav Y, Segev A, Feinberg M, Elian D.

Left ventricular apical ballooning outcomes and long term follow up, the Sheba experience 2002-2010.

The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.

- 42) Moriel M, Matetzky S, Segev A, Kornowski R, Danenberg H, Buby L, Goldenberg I, Tzivoni D, Gottlieb S.

Thrombus aspiration in STEMI patients undergoing primary PCI – Insights from ACSIS 2010.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

- 43) Fefer P, Matetzky S, Kornowski R, Danenberg H, Gottlieb S, Buby L, Zahger D, Meerkin D, Cafri C, Atar S, Segev A

Radial intervention in patients with acute coronary syndromes – results from ACSIS PCI 2010.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

44) Beigel R, Matetzky S, Fefer P, Danenberg H, Gottlieb S, Kornowski R, Zahger D, Goldenberg I, **Segev A**

Predictors of high-risk angiographic findings in patients with non ST-elevation ACS.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

45) Goitein O, Di-Segni E, Konen E, Eshet Y, Guetta V, **Segev A**, Hamdan A. The Additive value of CT prior to transcatheter aortic valve implantation (TAVI) procedure.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

46) Jaffe R, Finkelstein A, Lewis B, Guetta V, Khader N, Rubinshtein R, Halon D, **Segev A**.

Left main stenting in patients with severe aortic stenosis prior to percutaneous valve interventions.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

47) Rozen G, Fefer P, Malachy A, Shinfeld A, Sternik L, Guetta V, Raanani E, **Segev A**.

Surgical aortic valve replacement for aortic stenosis in the era of transcatheter implantation.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

48) Danenberg H, Finkelstein A, Guetta V, Almagor Y, Nader K, Kerner A, Cafri C, George J, Rosenman Y, **Segev A**, Kornowski R

Transcatheter aortic valve implantation in Israel 2011: Preliminary results of the national Israeli ongoing registry.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

49) Beigel R, Brosh S, Goitein O, Guttman E, **Segev A**, Oeiru D, Konen E, Gerber Y, Hod H, Matetzky S

Non-obstructive coronary artery disease upon computed tomography in patients with acute chest pain.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

50) Herscovici R, Hod H, Matetzky S, Kuperstein R, Feinberg M, Grupper A, **Segev A**.

The effect of systemic hypothermia on myocardial salvage in patients with STEMI and primary PCI.

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

51) Shinfeld A, Guetta V, **Segev A**, Hai I, Spiegelstein D, Garniec A, Rimon U, Khaitovich B, Preisman S, Nachum ER, Raanani E.

Hybrid cardiac operating room: First year experience

The 59<sup>th</sup> Annual Meeting of The Israel Heart Society, 2012, Tel-Aviv, Israel.

#### **G. OTHER PUBLICATIONS**

1) **Segev A**, Mekori YA.

The Cardiac Insufficiency Bisoprolol Study II. Letter.

Lancet 1999, 353:1361

2) **Segev A**.

Campylobacter-associated myopericarditis with ventricular arrhythmia in a young hypothyroid patient. Letter. Isr Med Assoc J 2011;13:128

3) **Segev A**, Lotan C.

The Israel Heart Society.

Circulation J 2012;76:2055-7

**INVITED LECTURES:**

- 1)** Three clinical aspects of light chain myeloma. Meir Hospital Medical Grand Rounds, Kfar-Saba, Israel. March 1998.
- 2)** Genetics of hypertrophic cardiomyopathy and cardiac arrhythmias. Meir Hospital Medical Grand Rounds, Kfar-Saba, Israel. January 2002.
- 3)** Myocardial necrosis after percutaneous coronary interventions. St. Michael's Hospital Cardiology Grand Rounds, Toronto, Ontario. February 2003.
- 4)** Advances in biomedical technologies in Israel. Beth David Synagogue, Toronto, Ontario. April 2003.
- 5)** TAFI and perlecan – two new players in restenosis. St. Michael's Hospital Cardiology Research Rounds, Toronto, Ontario. January 2004.
- 6)** Medical and scientific accomplishments from Israel. Jewish Community Center, London, Ontario. February 2004.
- 7)** Collagenase enzymatic degradation for the treatment of chronic total occlusions. St. Michael's Hospital Cardiology Research Rounds, Toronto, Ontario. May 2004.
- 8)** Plaque digestion with collagenase: an alternative treatment strategy for chronic total occlusions. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. Oct 2004.
- 9)** Perlecan inducers: a novel approach for drug-eluting stents. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. Oct 2004.
- 10)** Interventional 'digestion' of chronic total occlusions. GCI – Global Cardiovascular Interventions, Frankfurt, Germany. Nov 2004
- 11)** Collagenase enzymatic degradation for the treatment of chronic total occlusions. Chaim Sheba Medical Center Cardiology Rounds, Tel Hashomer, Israel. December 2004.
- 12)** Coronary interventions in the elderly. Sheba Medical Center Lectures to the Community ("Sheba on the morning"). May 2005.
- 13)** Innovations in interventional Cardiology. Sheba Medical Center nurses rounds. June 2005

- 14)** Chronic Total Occlusions: Exploring the Final Frontier. Pharmacologic Dissolution: Collagenase. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA. October 2005.
- 15)** Collagenase enzymatic degradation and augmentation of microvessels for the treatment of chronic total occlusions. Hadassah Medical Center Cardiology Rounds, Jerusalem, Israel. February 2006
- 16)** Adjunctive therapies in patients undergoing primary PCI beyond glycoprotein IIb/IIIa inhibitors. Annual meeting of the Israeli Heart Society councils for interventional cardiology and intensive cardiac care. Tel Aviv, Israel. March 2006.
- 17)** Update on acute coronary syndromes. Preparation course for foreign medical graduates. Hasharon Hospital. October 2006
- 18)** Pericardial diseases. Preparation course for foreign medical graduates. Hasharon Hospital. October 2006
- 19)** Acute Coronary Syndromes – Update. Preparation course for Internal Medicine residents. Dan Acadia, Herzeliya, Nov 2006.
- 20)** Acute Coronary Syndromes – Update. Preparation course for Internal Medicine residents. Dan Acadia, Herzeliya, March 2007.
- 21)** Technical strategies in CTO revascularization. 1<sup>st</sup> Israeli CTO meeting. Jerusalem, May 2007
- 22)** Primary percutaneous coronary intervention in patients with occluded vein grafts. EuroPCR, May 2007, Barcelona, Spain.
- 23)** Debate – drug eluting stents in diabetics – the focus is the disease. Annual meeting of the Israeli Heart Society council for Interventional Cardiology. Eilat, July 2007.
- 24)** Non ST-elevation acute coronary syndromes – Update. Preparation course for cardiology residents. Israel Heart Society. Qesaria, November 2007
- 25)** Acute Coronary Syndromes – Update. Preparation course for Internal Medicine residents. Dan Acadia, Herzeliya, March 2008
- 26)** Mechanisms of restenosis. Tel Aviv University Cardiology CME course. March 2008

- 27)** FIM Multicenter Randomized Study: The Ovalum CiTop™ Guidewire System for Recanalization of Peripheral CTOs. EuroPCR, May 2008, Barcelona, Spain
- 28)** PCI in coronary artery disease – 2008 Update. Preperation course for cardiology residents. Israel Heart Society. Qesaria, November 2008 **29)** Percutaneous aortic valve implantation. Point Counter Point (PCP) Meeting, The Green House, Tel Aviv, February 2009
- 30)** Pathophysiology of acute coronary syndromes. Interventional Cardiology course for cath lab nurses and technicians on behalf of the Interventiona Cardiology Working Group. Meir Hospital, March 2009
- 31)** Coronary Anatomy. Interventional Cardiology course for cath lab nurses and technicians on behalf of the Interventional Cardiology Working Group. Meir Hospital, March 2009
- 32)** When to use a DES, to whom and which stent?  
Lesion-based Perspective. Annual meeting of the Israeli Heart Society council for Interventional Cardiology. Tel-Aviv, March 2009
- 33)** FIM Study: The Ovalum CiTop™ Expander™ Guidewire for Recanalization of Coronary CTOs. EuroPCR, May 2009, Barcelona, Spain
- 34)** Myocardial necrosis in patients with angiographically normal coronary arteries. Tel Aviv University Cardiology CME course. May 2009
- 35)** Overview of Cardiology topics. Tel Aviv University Internal Medicine CME. Preperation Course for Internal Medicine Residents. May 2009
- 36)** The role of thrombus aspiration in patients undergoing primary PCI. Montreal Interventional Cardiology Meeting, Montreal, Canada, June 2009
- 37)** The Ovalum CiTop guide-wire for recanalization of chtonic total occlusions. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA, USA, September 2009
- 38)** Therapeutic options for late DES failure. 6th International Meeting on Intensive Cardiac Care, Tel-Aviv, Israel, October 2009
- 39)** Basic coronary anatomy. Tel Aviv University Cardiology CME course. October 2009

- 40)** Mechanisms of restenosis. Tel Aviv University Cardiology CME course. November 2009
- 41)** Pathophysiology of atherosclerosis and acute coronary syndromes. Cardiology course for MSc students in medical sciences, Tel-Aviv University. November 2009
- 42)** PCI in coronary artery disease – 2009 Update. Preparation course for cardiology residents. Israel Heart Society. Qesaria, November 2009
- 43)** Risk management in cardiology. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2009.
- 44)** Cardiac catheterization and hemodynamics. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2009.
- 45)** The Ovalum CiTop Guidewire: Device Evolution, Peripheral, and Coronary Applications. 7<sup>th</sup> International Chronic Total Occlusion Summit, New York, NY, USA. February 2010
- 46)** Overview of unprotected left main stenting. Annual meeting of the Israeli Working Group in Interventional Cardiology. Jerusalem, Israel. February 2010
- 47)** Update in Non-ST Elevation Acute Coronary Syndrome. Update in Cardiology day, Israel Heart Society. Tel-Aviv, Israel. March 2010.
- 48)** My most challenging cases. Simultaneous primary PCI during CPR and systemic cooling. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010
- 49)** Meeting the experts. Presentation of complex cases of transcatheter aortic valve implantation (TAVI). Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010
- 50)** The Ovalum CiTop™ 0.014 guide-wire – device evolution and coronary and peripheral application. Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC, USA, September 2010

- 51)** Complex PCI in patients on chronic anti-coagulation. Biotronik Focus Group, Zurich, Switzerland, October 2010
- 52)** PCI in coronary artery disease – 2010 Update. Preperation course for cardiology residents. Israel Heart Society. Qesaria, November 2010
- 53)** Pathophysiology of atherosclerosis and acute coronary syndromes. Cardiology course for MSc students in medical sciences, Tel-Aviv University. November 2010
- 54)** Coagulation system and hemostasis in cardiology. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2010.
- 55)** Risk management in cardiology. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2010
- 56)** Cardiac catheterization and hemodynamics. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2010.
- 57)** Mechanisms of restenosis. Tel Aviv University Cardiology CME course. Februray 2011.
- 58)** Cardiac hemodynamics. Internal medicine grand rounds. Sheba Medical Center, Tel Hashomer, Israel. February 2011
- 59)** Novel procedures in interventional cardiology. Tel Aviv University Internal Medicine CME course. April 2011
- 60)** ACSIS 2010 - Interventional Management in ACS in Special Populations. The 58<sup>th</sup> Annual Meeting of The Israel Heart Society, 2011, Tel-Aviv, Israel.
- 61)** Anti-thrombotic therapy in hemophilia patients undergoing PCI. Intensive Cardiac Care and Interventional Cardiology Working Groups Meeting, 2011, Tel Aviv, Israel
- 62)** What's available for transradial access? The 2<sup>nd</sup> Israeli Workshop in Transradial intervention, 2011, Jerusalem, Israel.

- 63)** Transcatheter Aortic Valve Implantation: Patient selection and strategies for optimal outcomes. International Summit on Imaging and Intervention in Cardiology (ISIIC), September 2011, Katowice, Poland
- 64)** Interventional Cardiology Update 2011. Preperation course for cardiology residents. Israel Heart Society. October 2011, Neve Ilan. Israel
- 65)** Cardiac Hemodynamics. Cardiology Course for 4<sup>th</sup> year medical students (YAKAR). Sackler School of Medicine, Tel-Aviv University. November 2011.
- 66)** Risk management in cardiology. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2011
- 67)** Cardiac catheterization and hemodynamics. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2011.
- 68)** Stent Thrombosis in ther era of new anti-platelet therapies. Israel Heart Society Scientific Meeting, January 2012, Eilat, Israel
- 69)** A case of severe aortic stenosis and low EF. Isreal Heart Society Scientific Meeting, January 2012, Eilat, Israel
- 70)** Novel anti-platelets therapies. Maccabi Health Services (pharmacists). Tel Aviv, May 2012
- 71)** Myocardial necrosis in patients with normal coronary arteries. Tel Aviv University Cardiology CME course. May 2012.
- 72)** Update in Interventional Cardiology. Update day for family physician of the Israel Heart Society, Tel Aviv, June 2012.
- 73)** Update in percutaneous valvular interventions. Update day for family physician of the Israel Heart Society, Tel Aviv, June 2012.
- 74)** Update in coronary interventions. The 31<sup>st</sup> Conference for General and Family Medicine. Tel Aviv, July 2012.
- 75)** Interventional Cardiology Update 2012. Preperation course for cardiology residents. Israel Heart Society. October 2012, Neve Ilan. Israel

**76)** The optimal mechanical adjuvant therapy during primary PCI. Acute cardiac Care & Interventional Cardiology WGs Meeting, December 2012, Tel Aviv,

Israel

**77)** Risk management in cardiology. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv University. December 2012

**78)** Cardiac catheterization and hemodynamics. Cardiology Course for 2<sup>nd</sup> year medical students - 4-year program. Sackler School of Medicine, Tel-Aviv

University. December 2012. **79)**

### **PATENTS**

- 1) United States Patent Serial No. 20070154555. Augmentation of intraluminal microvessel formation to facilitate guide wire crossing in chronic total occlusions.
- 2) United States Patent Serial No. 2005097177. Collagenase administration to facilitate guide wire crossing in chronic total occlusions.

### **REVIEWER OF SCIENTIFIC JOURNALS:**

- 1) Cardiovascular Research: 1999-present
- 2) Catheterization and Cardiovascular Interventions: 2003 - present
- 3) American Journal of Cardiology: 2003-present
- 4) Current Drug Targets – Cardiovascular & Haematological Disorders: 2003
- 5) Cardiovascular Pathology: 2004-present
- 6) Journal of the American College of Cardiology: 2004 – present
- 7) Lasers in Medical Science: 2006
- 8) Future-Drugs: 2007
- 9) Israel Medical Association Journal (IMAJ) – 2010 - present
- 10) European Journal of gastroenterology and Hepatology: 2009
- 11) Cardiovascular Revascularization Medicine – 2012 – present
- 12) Annals, Academy of Medicine, Singapore – 2008 - present

**FACULTY MEMBER IN INTERNATIONAL SCIENTIFIC MEETINGS:**

- 1) Transcatheter Cardiovascular Therapeutics (TCT), 2003, Washington, DC, USA
- 2) Transcatheter Cardiovascular Therapeutics (TCT), 2004, Washington, DC, USA
- 3) GCI – Global Cardiovascular Interventions, 2004, Frankfurt, Germany
- 4) Transcatheter Cardiovascular Therapeutics (TCT), 2005, Washington, DC, USA
- 5) 1<sup>st</sup> Israeli CTO meeting, 2007, Jerusalem, Israel
- 6) EuroPCR, 2007, Barcelona, Spain
- 7) 2<sup>nd</sup> Israeli CTO meeting, 2008, Jerusalem, Israel
- 8) EuroPCR, 2008, Barcelona, Spain
- 9) Innovations in Cardiovascular Interventions (ICI), 2008, Tel Aviv, Israel
- 10) EuroPCR, 2009, Barcelona, Spain
- 11) Montreal Interventional Cardiology Meeting, 2009, Montreal, Canada
- 12) Transcatheter Cardiovascular Therapeutics (TCT), 2009, San Francisco, CA, USA
- 13) 6<sup>th</sup> International Meeting on Intensive Cardiac Care, 1009, Tel-Aviv, Israel
- 14) Innovations in Cardiovascular Interventions (ICI), 2009, Tel Aviv, Israel
- 15) 7<sup>th</sup> International Chronic Total Occlusion Summit, February 2010, New York, NY, USA
- 16) EuroPCR, 2010, Paris, France
- 17) Montreal Interventional Cardiology Meeting, 2010, Montreal, Canada
- 18) Transcatheter Cardiovascular Therapeutics (TCT), 2010, Washington, DC, USA
- 19) Innovations in Cardiovascular Interventions (ICI), 2010, Tel Aviv, Israel
- 20) INDIA Live, 2011, Mumbai, India
- 21) Cardiovascular Revascularization Technologies (CRT), 2011, Washington, DC, USA

- 22) International Summit on Imaging and Intervention in Cardiology (ISIIC), 2011, Katowice, Poland
- 23) Transcatheter Cardiovascular Therapeutics (TCT), 2011, San Francisco, CA, USA
- 24) Innovations in Cardiovascular Interventions (ICI), 2011, Tel Aviv, Israel
- 25) American College of Cardiology (ACC.12) Scientific Congress, 2012, Chicago, IL, USA
- 26) EuroPCR, 2012, Paris, France
- 27) The 61<sup>st</sup> International Congress of The European Society of Cardiovascular and Endovascular Surgery – ESCVS, 2012, Dubrovnik, Croatia
- 28) Transcatheter Cardiovascular Therapeutics (TCT), 2012, Miami, FL, USA
- 29) Innovations in Cardiovascular Interventions (ICI), 2012, Tel Aviv, Israel
- 30) American College of Cardiology (ACC.13) Scientific Congress, 2013, San Francisco, CA, USA

**CONSULTATION TO INDUSTRY:**

- 1) Past Consultant, Biocontrol Ltd., Yahud, Israel
- 2) Consultant, Rad Biomed incubator Ltd., Kiriati Atidim, Tel-Aviv, Israel
- 3) Past Director of Interventional Cardiology Forum, StarMed Ltd., Israel ([www.starmed.co.il/Forum/107](http://www.starmed.co.il/Forum/107))
- 4) Past Medical Director, ArioMedica Ltd. Kiriati Atidim, Tel-Aviv Medical
- 5) Past consultant, Top Spin Medical Ltd., Lod, Israel
- 6) Past Medical Director, Ovalum Ltd. Rehovot, Israel
- 7) Medical Advisory Board, ValtechCardio Ltd. Or-Yehuda, Israel
- 8) Consultant, Israel Triventures, Herzelya, Israel
- 9) Advisory Board, Sanofi, Israel
- 10) Consultant (Focus Group), Biotronik Ltd., Switzerland
- 11) Global Advisory Board, Medtronic Ltd, Santa Rosa, CA, USA
- 12) Advisory Board, Elly-Lilly Ltd, Israel
- 13) Advisory Board, Bayer Israel Ltd., Israel
- 14) Advisory Board, Astra-Zeneca Israel Ltd., Israel

- 15) Advisory Board, MSD Israel Ltd., Israel
- 16) Proctor for TAVI, Edwards LifeSciences Ltd., Europe.
- 17) Advisory Board, Pfizer Israel Ltd., Israel